

Gibson Dunn Advises Jade Biosciences on \$135 Million Private Placement

Firm News | October 15, 2025

Gibson Dunn represented Jade Biosciences, Inc. in connection with a private placement of securities generating aggregate gross proceeds of approximately \$135 million to both new and existing investors including Janus Henderson Investors, Fairmount, RA Capital Management, Marshall Wace, Aberdeen Investments, Great Point Partners, LLC, Venrock Healthcare Capital Partners, Samsara BioCapital, Avidity Partners, and several other leading healthcare investors.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade is based in Massachusetts.

Gibson Dunn regularly advises life sciences companies and healthcare investors on private placements and capital markets transactions in the biotechnology sector.

The Gibson Dunn team included Ryan Murr, Branden Berns, Nick Linke, Candice Johnson, Jasmine Vitug, and Lauren Guzman.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Nicholas G. Linke](#)

[Candice D. Johnson](#)

[Jasmine L. Vitug](#)

[Lauren Guzman](#)

Related Capabilities

[Capital Markets](#)

[Mergers and Acquisitions](#)

[Life Sciences](#)

[Private Equity](#)